当前位置: 首页 > 药物分子靶点数据库 反馈纠错 帮助中心

一个药物有多个靶点,靶点与靶点采用分号隔开

导出数据
药物名称 分子靶点 ATC编码 适应症
ZYC300 For the treatment of various forms of cancer.
Zalutumumab Epidermal growth factor receptor
XTL-001 Investigated for use/treatment in hepatitis (viral, B).
XOMA 052 Interleukin-1 beta Investigated for use/treatment in diabetes mellitus type 2.
VPM4001 Investigated for use/treatment in prostate cancer.
VIR201 Interferon gamma Investigated for use/treatment in HIV infection.
Velaglucerase alfa Glucosylceramidase A16AB10 Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.
Vedolizumab Integrin alpha-4;Integrin beta-7 L04AA33 Vedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate respon
VB2-011 Investigated for use/treatment in cancer/tumors (unspecified).
Vasopressin Vasopressin V2 receptor;Vasopressin V1a receptor;Vasopressin V1b receptor H01BA06 For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding
Ustekinumab Interleukin-12 subunit beta;Interleukin-23 (Protein Group) L04AC05 Ustekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adul
Urokinase Plasminogen;Urokinase plasminogen activator surface receptor;Urokinase-type plasminogen activator;Tissue-type plasminogen activator;Plasminogen activator inhibitor 1;Plasminogen activator inhibitor 2;Plasma serine protease inhibitor;Low-density lipoprotein receptor-related protein 2;Suppressor of tumorigenicity 14 protein;Nidogen-1 B01AD04 Urokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.
Urofollitropin Follicle-stimulating hormone receptor G03GA04 For treatment of female infertility
Ty800 For the production of immunity to Salmonella typhi, the cause of typhoid fever.
Turoctocog alfa
Tuberculin Purified Protein Derivative Indicated as an aid in the detection of infection with Mycobacterium tuberculosis.
TRX1 Investigated for use/treatment in autoimmune diseases.
Trastuzumab emtansine Receptor tyrosine-protein kinase erbB-2 L01XC14 Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
Trastuzumab Receptor tyrosine-protein kinase erbB-2;Epidermal growth factor receptor;Complement C1r subcomponent;Complement C1q subcomponent subunit A;Complement C1q subcomponent subunit B;Complement C1q subcomponent subunit C;Complement C1s subcomponent;High affinity immunoglobulin gamma Fc receptor I;Low affinity immunoglobulin gamma Fc region receptor II-a;Low affinity immunoglobulin gamma Fc region receptor II-b;Low affinity immunoglobulin gamma Fc region receptor II-c;Low affinity immunoglobulin gamma Fc region receptor III-B;Low affinity immunoglobulin gamma Fc region receptor III-A L01XC03 For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
Tositumomab B-lymphocyte antigen CD20;Low affinity immunoglobulin gamma Fc region receptor III-B;Complement C1r subcomponent;Complement C1q subcomponent subunit A;Complement C1q subcomponent subunit B;Complement C1q subcomponent subunit C;Low affinity immunoglobulin gamma Fc region receptor III-A;High affinity immunoglobulin gamma Fc receptor I;Low affinity immunoglobulin gamma Fc region receptor II-a;Low affinity immunoglobulin gamma Fc region receptor II-b;Low affinity immunoglobulin gamma Fc region receptor II-c For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)